Visit our poster #ASCO25 Nikhil Vojjala, MD .on SPM in CART

#ASCO25 posters. Our rising star hospitalist Muhammad Atif Khan MD presenting database study on #CMV and #CART. We highlight the serious impact of CMV infection in CAR-T recipients, ⬆️ mortality, ⬆️ hospital stays, high association with ICANS/ neuro complications. Findings support need

Check out our Poster #63 #ASCO discussing the largest real-world study on t-MN incidence with RAI (Pluvicto and Lutathera) in n=2370. Overall risk is 1.6% at a median follow-up of 27.3 months: 1.9% with Lutathera, 1.2% with Pluvicto.Nikhil Vojjala, MD Vijendra Singh

Excellent discussion. Audience questions mostly future of #CART, where will it be used in next decade and scope with non cancer diseases KU Cancer Center #HemOncReview Prakash Neupane Al-Ola A Abdallah MD (USMIRC) Anusha MD Abdulraheem Yacoub

Global access to novel MM therapies remains challenging, barriers and suggested strategies to bridge the gap. Global Access to Multiple Myeloma Therapies | JCO Global Oncology ascopubs.org/doi/full/10.12…

📢 Excited to share our multicenter study just published in Clinical Lymphoma, Myeloma & Leukemia: “Real-world outcomes of sequential BCMA therapies in RRMM after belantamab” 🔗 clinical-lymphoma-myeloma-leukemia.com/article/S2152-… Shout-out to Hamza Hashmi Racheldileo With: Yue Yin Christopher Strouse

🚨 Major congratulations! 🚨 Dr. Joseph McGuirk, Division Director of Hematologic Malignancies & Cellular Therapeutics, has been awarded the prestigious 2025 KCU Alumni Lifetime Achievement Award! A true pioneer in CAR T therapy and Malignant Hematology — well deserved! 👏🎉

This is a major win for patients . we have been advocating this with our publications on access ! Finally - REMS is revised and product labeling revision to include 2 weeks monitoring and driving restriction and not 4 weeks. 👍🏼 -monitor patients for at least 2 wk, with daily

ICE-T: Where immune cell therapy meets bold ideas, real talk, and the people actually doing the work. Don’t just hear about it—be there. Whether you're in the clinic or the classroom, ICE-T delivers practical updates for nurses, APPs, and physicians in both community and academic

Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management onlinelibrary.wiley.com/doi/10.1002/aj… #AML #leusm

Just out: key safety reporting patterns for TCEs in multiple myeloma Faiza Humayun Khan Nausheen Ahmed MD Al-Ola A Abdallah MD (USMIRC) KU Cancer Center Zahra M, PharmD, MBA, BCOP, FHOPA Cortex Innovation #hemeonc cureus.com/articles/38058…

🎉🚀 The #ICET Conference is live in Orlando, FL! 🌞 Explore #myeloma, #lymphoma, #leukemia & #solidTumors. Discover the latest in bispecifics, CAR-T, & T cell engagers! 🧬✨ Learn how to bring these to your clinic. #ICET2025

Through Every Challenge, They’ve Been My Strength - Al-Ola A Abdallah Al-Ola A Abdallah MD (USMIRC) oncodaily.com/blog/al-ola-a-… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews

📣Our letter “#REMS to #Reach” is out. . Bilal Abid, MD, MS. 🌟🌟In our view (personal opinion), the modification of REMS is more than just a regulatory change—it is a catalyst for democratizing access, reducing delivery costs and patient burden, academic-community-industry